BR0212019A - Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. - Google Patents
Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form.Info
- Publication number
- BR0212019A BR0212019A BR0212019-4A BR0212019A BR0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- dosage form
- dosage
- preparing
- dosage forms
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 7
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 239000000014 opioid analgesic Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
"FORMAS DE DOSAGEM, MéTODOS PARA O TRATAMENTO DA DOR, MéTODOS DE PREPARAçãO DE UMA FORMA DE DOSAGEM E MéTODOS PARA IMPEDIR O ABUSO DE UMA FORMA DE DOSAGEM". Trata-se de métodos e composições para impedir o abuso de formas de dosagem de um analgésico de opióide e um antagonista de opióide que inclui pelo menos um agente aversivo em uma quantidade eficaz para impedir que um usuário em abuso administre uma forma alterada da dita forma de dosagem intravenosamente, intranasalmente, e/ou oralmente."DOSAGE FORMS, METHODS FOR THE TREATMENT OF PAIN, METHODS FOR PREPARING A DOSAGE FORM AND METHODS TO PREVENT ABUSE OF A DOSAGE FORM". These are methods and compositions for preventing abuse of dosage forms of an opioid analgesic and an opioid antagonist that includes at least one aversive agent in an amount effective to prevent an abused user from administering an altered form of said form. intravenously, intranasally, and / or orally.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31053701P | 2001-08-06 | 2001-08-06 | |
US31051601P | 2001-08-06 | 2001-08-06 | |
US31051501P | 2001-08-06 | 2001-08-06 | |
PCT/US2002/024934 WO2003013479A1 (en) | 2001-08-06 | 2002-08-06 | Compositions and methods to prevent abuse of opioids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212019A true BR0212019A (en) | 2005-08-09 |
Family
ID=27405462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212019-4A BR0212019A (en) | 2001-08-06 | 2002-08-06 | Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1414418A1 (en) |
JP (1) | JP2005501067A (en) |
KR (1) | KR20040060917A (en) |
AU (1) | AU2002319774B2 (en) |
BR (1) | BR0212019A (en) |
CA (1) | CA2456322A1 (en) |
DE (1) | DE20220910U1 (en) |
HU (1) | HUP0401195A3 (en) |
MX (1) | MXPA04001208A (en) |
WO (1) | WO2003013479A1 (en) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2241458C2 (en) | 1997-12-22 | 2004-12-10 | Эро-Селтик, С.А. | Combinations of agonist/antagonist for opioid |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CN1525851A (en) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | Abuse-resistant controlled-release opioid dosage form |
EP2311460A1 (en) | 2001-07-06 | 2011-04-20 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
SI1416842T1 (en) * | 2001-07-18 | 2009-06-30 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
ES2546010T3 (en) | 2002-04-05 | 2015-09-17 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
EP1492511B3 (en) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
DE10250083A1 (en) * | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Dosage form protected against abuse |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
MXPA05001826A (en) * | 2002-08-15 | 2005-04-19 | Euro Celtique Sa | Pharmaceutical compositions. |
DE10250088A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
DE10250084A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US9579286B2 (en) * | 2003-04-21 | 2017-02-28 | Purdue Pharma L.P. | Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
RU2350327C2 (en) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Compounds causing weight loss |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
BRPI0508769A (en) | 2004-03-30 | 2007-08-28 | Euro Celtique Sa | tamper-resistant dosage form comprising an adsorbent and an adverse agent |
DE102004019916A1 (en) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Anti-abuse drug-containing patch |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
CA2594373A1 (en) * | 2005-01-28 | 2006-08-03 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
FR2889810A1 (en) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
FR2883179B1 (en) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | COATED TABLET |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
BRPI0618918B8 (en) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | use of a first compound and a second compound to treat a blood glucose condition |
EP1810714A1 (en) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of a combination of heroin and naloxon for drug substitution |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP2061448B1 (en) * | 2006-06-05 | 2019-07-17 | Nalpropion Pharmaceuticals, Inc. | Sustained release formulation of naltrexone |
US20070286900A1 (en) * | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
AU2014200910B2 (en) * | 2006-10-03 | 2017-02-09 | Arbutus Biopharma Corporation | Lipid containing formulations |
RU2009116834A (en) | 2006-11-09 | 2010-12-20 | Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) | METHOD FOR ADMINISTRATION OF MEDICINES FOR REDUCING WEIGHT |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US8273798B2 (en) * | 2007-06-04 | 2012-09-25 | Shear Kershman Laboratories | Tamper resistant lipid-based oral dosage form for opioid agonists |
CN105534936B (en) * | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | Abuse resistant drugs, methods of use and methods of preparation |
JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Methods for treating visceral fat conditions |
US8420700B1 (en) * | 2008-06-04 | 2013-04-16 | James M. Bausch | Tamper resistant lipid-based oral dosage form for sympathomimetic amines |
FR2938431B1 (en) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID |
US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
SG174286A1 (en) | 2009-03-10 | 2011-10-28 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
EP2456427B1 (en) | 2009-07-22 | 2015-03-04 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
PE20120572A1 (en) | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | HANDLING RESISTANT STABILIZED OXIDATION DOSAGE FORM |
FR2949062B1 (en) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES |
FR2949061B1 (en) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | FLOATING MICROGRANULES |
ES2762113T3 (en) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Methods of providing weight loss therapy in patients with major depression |
AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
CH705273B1 (en) | 2010-05-10 | 2016-06-15 | Euro Celtique Sa | Pharmaceutical composition - comprising hydromorphone and naloxone. |
CA2798885C (en) | 2010-05-10 | 2014-11-18 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
PE20131126A1 (en) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
AU2012219322A1 (en) * | 2011-02-17 | 2013-05-09 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
DK2736497T3 (en) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Shock-resistant tablet that provides an immediate release of a drug. |
EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
LT2838512T (en) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
ES2436344B1 (en) * | 2012-05-29 | 2014-08-07 | Onedose Pharma, S.L. | Pharmaceutical composition of diacetylmorphine and naloxone for oral administration |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
NZ716267A (en) | 2013-07-23 | 2017-05-26 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
CN105916505A (en) | 2013-11-13 | 2016-08-31 | 欧洲凯尔特公司 | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9132096B1 (en) * | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US10624888B2 (en) * | 2016-03-31 | 2020-04-21 | SpecGx LLC | Extended release, abuse deterrent dosage forms |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
KR102140493B1 (en) * | 2019-05-30 | 2020-08-03 | 충북대학교 산학협력단 | Composition for preventing or treating of bone diseases comprising denatonium compound |
AU2021299299A1 (en) * | 2020-07-01 | 2023-01-19 | Capsugel Belgium Nv | Dietary composition and method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
-
2002
- 2002-08-06 KR KR10-2004-7001878A patent/KR20040060917A/en not_active Application Discontinuation
- 2002-08-06 AU AU2002319774A patent/AU2002319774B2/en not_active Ceased
- 2002-08-06 DE DE20220910U patent/DE20220910U1/en not_active Expired - Lifetime
- 2002-08-06 HU HU0401195A patent/HUP0401195A3/en unknown
- 2002-08-06 WO PCT/US2002/024934 patent/WO2003013479A1/en not_active Application Discontinuation
- 2002-08-06 JP JP2003518489A patent/JP2005501067A/en active Pending
- 2002-08-06 EP EP02750438A patent/EP1414418A1/en not_active Withdrawn
- 2002-08-06 MX MXPA04001208A patent/MXPA04001208A/en unknown
- 2002-08-06 BR BR0212019-4A patent/BR0212019A/en not_active Application Discontinuation
- 2002-08-06 CA CA002456322A patent/CA2456322A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005501067A (en) | 2005-01-13 |
EP1414418A1 (en) | 2004-05-06 |
CA2456322A1 (en) | 2003-02-20 |
DE20220910U1 (en) | 2004-08-05 |
HUP0401195A2 (en) | 2004-10-28 |
WO2003013479A1 (en) | 2003-02-20 |
KR20040060917A (en) | 2004-07-06 |
AU2002319774B2 (en) | 2005-04-21 |
HUP0401195A3 (en) | 2006-11-28 |
MXPA04001208A (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212019A (en) | Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. | |
BR0212020A (en) | Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form | |
BRPI0414876A (en) | pharmaceutical compounds and compositions for the prevention of overdose or abuse and their uses | |
NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
BR0207024A (en) | Fast-acting drug to treat sexual dysfunction | |
WO2002098370A3 (en) | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders | |
WO2002058620A3 (en) | Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant | |
CY1107615T1 (en) | ANTI-HYPERTENSIONS AND ANTI-VEGETABLE FACTORS | |
BR0009647A (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers | |
CA2548834A1 (en) | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same | |
BR0008847A (en) | Analgesic compositions comprising antiepileptic compounds, and methods of using them | |
WO2003094836A3 (en) | Methods and products for enhancing immune responses using imidazoquinoline compounds | |
BR0013122A (en) | Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions | |
WO2004009015A3 (en) | Combination therapy for the treatment of obesity | |
PT1286671E (en) | COMPOSITIONS FOR THE TREATMENT OF CANCER COLORRECTALQUE UNDERSTAND TALIDOMIDA AND IRINOTECAN | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
BR0307508A (en) | Compound, pharmaceutical composition, and methods of treating or preventing pain and inflammation and treating disease | |
SE0002754D0 (en) | New pharmaceutical combination formulation and method of treatment with the combination | |
WO2006036770A3 (en) | Combination therapy for the treatment of obesity | |
BR9912508A (en) | Transdermal methods and compositions for pain relief | |
AR034900A1 (en) | USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT | |
AU7226301A (en) | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics | |
BRPI0412919A (en) | combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders | |
WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |